(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Supreme Court's Decision Sparks Biden's Call for Inclusive Education

June 30th, 2023

President Biden has announced a series of actions aimed at promoting educational opportunity and diversity in colleges and universities. The recent Supreme Court's decision in two cases — Students for Fair Admissions Inc. (SFFA) v. President an. Read more

Breaking: Renalytix's KidneyIntelX.dkd FDA-Approved, VSE Secures Up to $565M Contract

June 29th, 2023

Shares of Renalytix plc (Nasdaq: RNLX) surged over 25% in after-hours trading following the company's announcement of receiving De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.. Read more

Surging and Slumping: Aurinia Pharmaceuticals and Root Make Headlines

June 29th, 2023

Shares of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) witnessed a significant surge of over 10% in after-hours trading, driven by the company's announcement of initiating an exploration of strategic alternatives. The Board of Aurinia will carefull. Read more

Earnings Buzz and Reactions: Accolade, Progress Software, and Nike

June 29th, 2023

Accolade, Inc. (Nasdaq: ACCD) released its first-quarter fiscal 2024 earnings report, revealing a loss of $0.52 per share, which was better than the consensus estimate of a loss of $0.62 per share. The company also reported quarterly sales of $93.20 . Read more

SEC Charges Former Pfizer Statistician with Insider Trading Ahead of COVID-19 Announcement

June 29th, 2023

Employee and friend traded ahead of Pfizer’s “game-changer” announcement on the success of its Paxlovid trial FOR IMMEDIATE RELEASE 2022-123 Washington D.C. / CRWE PRESS RELEASE / June 29, 2023 -  The Securities and Exch. Read more

BREAKING: BioXcel's Regulatory Inquiry Status Sends Shares Tumbling

June 29th, 2023

Shares of BioXcel Therapeutics, Inc.? (Nasdaq: BTAI) plunged by over 50% in premarket trading following the company's disclosure of a regulatory inquiry into the development of BXCL501, as revealed in a regulatory filing with the SEC. Despite this. Read more

Joby's Pre-Market Surge, Nano Dimension's Milestone Quarter: What You Need to Know

June 29th, 2023

Shares of Joby Aviation, Inc. (NYSE: JOBY) experienced a significant surge of over 10% in pre-market trading following the announcement of an equity investment by SK Telecom Co., Ltd.? (NYSE: SKM), a prominent telecommunications company in South Kore. Read more

Earnings Beat: BlackBerry, Greenbrier, and Acuity Brands in the Spotlight

June 29th, 2023

Shares of BlackBerry Limited (NYSE: BB) experienced a significant surge of over 10% in pre-market trading following the release of better-than-expected financial results. The company delivered a surprise profit for the first quarter of fiscal 2024. Read more

Bullishness: ZI, GPC, SQSP, DE, VVI, WIX, ARRY, GDDY - Top Buy Ratings

June 29th, 2023

ZoomInfo Technologies Inc. (Nasdaq: ZI), a leading provider of go-to-market intelligence solutions, received coverage initiation from Needham with a Buy rating and a price target of $35.  Despite closing at $25.61 on Wednesday, the stated pri. Read more

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

June 28th, 2023

Silver Spring, MD / CRWE PRESS RELEASE / June 28, 2023 -  Today, the U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treat. Read more